Deng S, et al. - Researchers determined outcomes including efficacy and safety of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) vs CHOP plus etoposide (CHOPE) in patients with peripheral T-cell lymphoma (PTCL). For the meta-analysis, they selected a total of five prospective or retrospective articles with 1,560 patients. As per outcomes, CHOP and CHOPE groups displayed no differences in therapeutic effect with regards to complete response, partial response, overall response rate. However, the CHOPE group had significantly increased AEs (anemia and thrombocytopenia) than the CHOP group.